Oppenheimer initiated coverage of Capricor Therapeutics with an Outperform rating and $14 price target. The firm notes that top line results from the Phase 3 trial for lead candidate CAP-1002 in Duchenne muscular dystrophy DMD are expected in Q4 and it anticipates success for this “off-the-shelf” cell therapy. The firm forecasts about $1B in U.S. net sales in 2030 through partner NS Pharma and believes 1002’s growing revenue stream will support the advancement of the company’s preclinical exosome technology, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics price target raised to $25 from $24 at Ladenburg
- Capricor Therapeutics reports Q1 EPS (31c), consensus (11c)
- Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- CAPR Earnings this Week: How Will it Perform?
- Capricor Therapeutics to present exosome platform updates